2022
Ethical analysis examining the prioritisation of living donor transplantation in times of healthcare rationing
Kulkarni S, Flescher A, Ahmad M, Bayliss G, Bearl D, Biondi L, Davis E, George R, Gordon E, Lyons T, Wightman A, Ladin K. Ethical analysis examining the prioritisation of living donor transplantation in times of healthcare rationing. Journal Of Medical Ethics 2022, 49: 389-392. PMID: 34983855, PMCID: PMC10314075, DOI: 10.1136/medethics-2021-107574.Peer-Reviewed Original ResearchConceptsTransplant communityDonor transplantsTransplant hospitalsSARS-CoV-2 infectionHealth systemEnd-stage liverSARS-CoV-2Exposure riskDonor transplantationTransplant proceduresUnited NetworkKidney diseaseDialysis centersElective proceduresPatient preparednessTransplantEarly detectionCOVID-19 pandemicRiskHospitalRecipientsTier 3BAcceptable riskCareImportant option
2021
Quantifying Risk Tolerance Among Potential Living Kidney Donors With the Donor-Specific Risk Questionnaire
Thiessen C, Gannon J, Li S, Skrip L, Dobosz D, Gan G, Deng Y, Kennedy K, Gray D, Mussell A, Reese PP, Gordon EJ, Kulkarni S. Quantifying Risk Tolerance Among Potential Living Kidney Donors With the Donor-Specific Risk Questionnaire. American Journal Of Kidney Diseases 2021, 78: 246-258. PMID: 33508397, DOI: 10.1053/j.ajkd.2020.11.028.Peer-Reviewed Original ResearchConceptsKidney failure riskKidney failureDonor evaluationRisk QuestionnaireGreater patient-centered carePotential Living Kidney DonorsRisk estimatesKidney transplant centersKidney donor evaluationMultivariable logistic regressionLiving Kidney DonorsTime of enrollmentPatient-centered careTransplant centersTransplant teamKidney donorsRisk groupsPatient engagementAbstractTextLogistic regressionStudy designLongitudinal mixed-methods studyRecipientsMixed-methods studyRisk threshold
2016
De Novo Belatacept in a Human Immunodeficiency Virus–Positive Kidney Transplant Recipient
Cohen E, Mulligan D, Kulkarni S, Tichy E. De Novo Belatacept in a Human Immunodeficiency Virus–Positive Kidney Transplant Recipient. American Journal Of Transplantation 2016, 16: 2753-2757. PMID: 27137752, DOI: 10.1111/ajt.13852.Peer-Reviewed Original ResearchConceptsRenal transplant recipientsTransplant recipientsHuman immunodeficiency virus–positive kidney transplant recipientHIV-positive renal transplant recipientsPositive renal transplant recipientsHIV-positive Black menActive antiretroviral agentsKidney transplant recipientsNew-onset diabetesHuman immunodeficiency virusImmunosuppressive regimensFirst transplantAntiretroviral agentsCalcineurin inhibitorsImmunodeficiency virusKidney donorsDrug interactionsTransplantRecipientsBlack menSuccessful casesDe novoBelataceptHypertensionHyperlipidemia
2015
Duration of Prophylaxis against Fungal Infection in Kidney Transplant Recipients
Guerra CM, Formica RN, Kulkarni S, Asch WS, Tichy EM. Duration of Prophylaxis against Fungal Infection in Kidney Transplant Recipients. Progress In Transplantation 2015, 25: 311-315. PMID: 26645924, DOI: 10.7182/pit2015929.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsTransplant recipientsDuration of admissionCandida esophagitisFungal infectionsAdult kidney transplant recipientsEpisodes of thrushDuration of prophylaxisRetrospective chart reviewPrimary outcome measureFisher's exact testAdministration of nystatinStudent's t-testChart reviewOutcome measuresExact testEsophagitisProphylaxisRecipientsInfectionProtocol changesT-testAdmissionTransplantP-valuePsychiatric and medical adverse events for kidney transplant recipients with lithium induced kidney disease
Zimbrean P, Formica R, Ash W, Lettieri D, Kulkarni S. Psychiatric and medical adverse events for kidney transplant recipients with lithium induced kidney disease. Journal Of Psychosomatic Research 2015, 78: 634. DOI: 10.1016/j.jpsychores.2015.03.148.Peer-Reviewed Original Research
2014
Opting out: confidentiality and availability of an ‘alibi’ for potential living kidney donors in the USA
Thiessen C, Kim YA, Formica R, Bia M, Kulkarni S. Opting out: confidentiality and availability of an ‘alibi’ for potential living kidney donors in the USA. Journal Of Medical Ethics 2014, 41: 506. PMID: 25368413, DOI: 10.1136/medethics-2014-102184.Peer-Reviewed Original Research
2010
Kidney Transplantation and HIV: Does Recipient Privacy Outweigh the Donor's Right to Information?
Formica RN, Asch WS, Wagner KR, Kulkarni S. Kidney Transplantation and HIV: Does Recipient Privacy Outweigh the Donor's Right to Information? Clinical Journal Of The American Society Of Nephrology 2010, 5: 924-928. PMID: 20203162, PMCID: PMC2863980, DOI: 10.2215/cjn.06820909.Peer-Reviewed Original ResearchConceptsHIV-positive individualsKidney transplantationMedical historyRecipient's medical historyAlternative treatment optionHIV statusKidney donorsTreatment optionsKidney donationConsensus groupTransplantationDonation procedureAbstractTextRecipient's rightRecipientsPotential donorsHealth informationPotential recipientsSpecific diseasesPanel reviewHIVDonors' rightsRiskDonorsState statues
2006
Living donor liver transplantation for pediatric and adult recipients
Kulkarni S, Malagò M, Cronin DC. Living donor liver transplantation for pediatric and adult recipients. Nature Reviews Gastroenterology & Hepatology 2006, 3: 149-157. PMID: 16511549, DOI: 10.1038/ncpgasthep0437.Peer-Reviewed Original Research
2003
Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsis
Kulkarni S, Naureckas E, Cronin DC. Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsis. Transplantation 2003, 75: 899-901. PMID: 12660522, DOI: 10.1097/01.tp.0000054842.34916.e8.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsSolid organ transplantsSevere sepsisDrotrecogin alfaTransplant recipientsMultisystem organ failureImmunosuppressed recipientsOrgan failurePatient populationEffective adjuvantProcoagulant responseSepsisHigh mortalityAlfaRecipientsTransplantConventional managementTreatmentInitial successAdjuvantMortality